NYMX Nymox Pharmaceutical Corporatio

4.73
0  -5%
Previous Close 4.99
Open 4.96
Price To book 0.00
Market Cap 232.96M
Shares 49,251,000
Volume 188,414
Short Ratio 25.18
Av. Daily Volume 201,889

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data released February 2016 met endpoint
NX-1207 long-term NX03-0040 trial
Low grade localized prostate cancer
Phase 3 endpoints met in extension trial July 2015. Noted March 28, 2017 that regulatory filing is due during the next few weeks.
NX-1207 Fexapotide
BPH